TrialBMC cancer2023

A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01).

Louise Skau Rasmussen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.